Table 9.
Item | Treatment1 |
P-value, t-test | Linear | Quadratic | P-value | |||||
---|---|---|---|---|---|---|---|---|---|---|
Ctr | Ox | OxL | OxM | OxH | SEM | |||||
MUC2 | 1.00 | 0.15∗,b | 0.71b | 0.42b | 2.19a | 0.147 | 0.001 | <0.001 | 0.080 | <0.001 |
ZO1 | 1.03 | 0.22∗,b | 0.34a,b | 0.41a | 0.27a,b | 0.063 | 0.013 | 0.413 | 0.006 | 0.039 |
Claudin-2 | 1.00 | 0.71b | 1.53b | 0.67b | 3.34a | 0.23 | 0.441 | 0.001 | 0.059 | 0.001 |
Nrf2 | 1.00 | 0.37b | 0.65b | 0.81b | 2.10a | 0.157 | 0.102 | <0.001 | 0.270 | 0.002 |
GCLM | 1.65 | 0.67b | 0.66b | 0.57b | 1.35a | 0.142 | 0.192 | 0.002 | 0.011 | 0.002 |
CAT | 1.00 | 0.50b | 0.87b | 0.96b | 2.30a | 0.146 | 0.121 | <0.001 | 0.182 | <0.001 |
SOD1 | 1.00 | 0.40b | 0.97b | 0.52b | 1.92a | 0.142 | 0.178 | <0.001 | 0.154 | <0.001 |
GPX2 | 1.00 | 1.01b | 1.40b | 1.28b | 2.21a | 0.131 | 0.970 | 0.003 | 0.494 | 0.018 |
GLRDX | 1.15 | 0.90b | 1.55b | 1.17b | 2.39a | 0.150 | 0.412 | 0.002 | 0.525 | 0.008 |
TXN | 1.14 | 0.77∗,b | 1.48a | 1.45a | 2.08a | 0.118 | 0.037 | <0.001 | 0.486 | 0.002 |
HO-1 | 1.00 | 0.45b | 0.87a,b | 0.84a,b | 1.29a | 0.087 | 0.101 | 0.001 | 0.715 | 0.007 |
NOX2 | 1.03 | 0.90a | 1.10a | 0.74a,b | 0.49b | 0.068 | 0.397 | 0.012 | 0.372 | 0.033 |
IL-8 | 0.80 | 0.36∗,c | 0.51b | 0.47b,c | 0.65a | 0.033 | 0.024 | <0.001 | 0.996 | 0.001 |
∗Means were significantly different compared with the control. Means within 4 treatments (Ox, OxL, OxM, and OxH) lacking a common superscript differ (P < 0.05).
Abbreviations: CAT, catalase; GCLM, glutamate–cysteine ligase modifier subunit; GLRDX, glutaredoxin; GPX2, glutathione peroxidase 2; HO-1, heme oxygenase-1; MUC2, mucin 2; Nrf2, nuclear factor erythroid 2–related factor 2; TXN, thioredoxin; SOD1, superoxide dismutase 1; ZO1, tight junction protein 1.
Ctr: basal diet; Ox: basal diet with oxidized oil; OxL: basal diet supplemented with oxidized oil and 200 ppm of quercetin; OxM: basal diet supplemented with oxidized oil and 400 ppm of quercetin; OxH: basal diet supplemented with oxidized oil and 800 ppm of quercetin.